Display options
Cite
Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46(1):13-58doi: 10.2165/00003088-200746010-00002.
Staatz, C. E., & Tett, S. E. (2007). Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clinical pharmacokinetics, 46(1), 13-58. https://doi.org/10.2165/00003088-200746010-00002
Staatz, Christine E, and Tett, Susan E. "Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients." Clinical pharmacokinetics vol. 46,1 (2007): 13-58. doi: https://doi.org/10.2165/00003088-200746010-00002
Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46(1):13-58. doi: 10.2165/00003088-200746010-00002. PMID: 17201457.
Copy Download .nbib Format: NLM
Share it on

Clin Pharmacokinet. 2007;46(1):13-58. doi: 10.2165/00003088-200746010-00002.

Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.

Clinical pharmacokinetics

Christine E Staatz, Susan E Tett

Affiliations

  1. School of Pharmacy, University of Queensland, Brisbane, Queensland, Australia. [email protected]

PMID: 17201457 DOI: 10.2165/00003088-200746010-00002

Abstract

This review aims to provide an extensive overview of the literature on the clinical pharmacokinetics of mycophenolate in solid organ transplantation and a briefer summary of current pharmacodynamic information. Strategies are suggested for further optimisation of mycophenolate therapy and areas where additional research is warranted are highlighted. Mycophenolate has gained widespread acceptance as the antimetabolite immunosuppressant of choice in organ transplant regimens. Mycophenolic acid (MPA) is the active drug moiety. Currently, two mycophenolate compounds are available, mycophenolate mofetil and enteric-coated (EC) mycophenolate sodium. MPA is a potent, selective and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), leading to eventual arrest of T- and B-lymphocyte proliferation. Mycophenolate mofetil and EC-mycophenolate sodium are essentially completely hydrolysed to MPA by esterases in the gut wall, blood, liver and tissue. Oral bioavailability of MPA, subsequent to mycophenolate mofetil administration, ranges from 80.7% to 94%. EC-mycophenolate sodium has an absolute bioavailability of MPA of approximately 72%. MPA binds 97-99% to serum albumin in patients with normal renal and liver function. It is metabolised in the liver, gastrointestinal tract and kidney by uridine diphosphate gluconosyltransferases (UGTs). 7-O-MPA-glucuronide (MPAG) is the major metabolite of MPA. MPAG is usually present in the plasma at 20- to 100-fold higher concentrations than MPA, but it is not pharmacologically active. At least three minor metabolites are also formed, of which an acyl-glucuronide has pharmacological potency comparable to MPA. MPAG is excreted into the urine via active tubular secretion and into the bile by multi-drug resistance protein 2 (MRP-2). MPAG is de-conjugated back to MPA by gut bacteria and then reabsorbed in the colon. Mycophenolate mofetil and EC-mycophenolate sodium display linear pharmacokinetics. Following mycophenolate mofetil administration, MPA maximum concentration usually occurs in 1-2 hours. EC-mycophenolate sodium exhibits a median lag time in absorption of MPA from 0.25 to 1.25 hours. A secondary peak in the concentration-time profile of MPA, due to enterohepatic recirculation, often appears 6-12 hours after dosing. This contributes approximately 40% to the area under the plasma concentration-time curve (AUC). The mean elimination half-life of MPA ranges from 9 to 17 hours. MPA displays large between- and within-subject pharmacokinetic variability. Dose-normalised MPA AUC can vary more than 10-fold. Total MPA concentrations should be interpreted with caution in patients with severe renal impairment, liver disease and hypoalbuminaemia. In such individuals, MPA and MPAG plasma protein binding may be altered, changing the fraction of free MPA available. Apparent oral clearance (CL/F) of total MPA appears to increase in proportion to the increased free fraction, with a reduction in total MPA AUC. However, there may be little change in the MPA free concentration. Ciclosporin inhibits biliary excretion of MPAG by MRP-2, reducing enterohepatic recirculation of MPA. Exposure to MPA when mycophenolate mofetil is given in combination with ciclosporin is approximately 30-40% lower than when given alone or with tacrolimus or sirolimus. High dosages of corticosteroids may induce expression of UGT, reducing exposure to MPA. Other co-medications can interfere with the absorption, enterohepatic recycling and metabolism of mycophenolate. Most pharmacokinetic investigations of MPA have involved mycophenolate mofetil rather than EC-mycophenolate sodium therapy. In population pharmacokinetic studies, MPA CL/F in adults ranges from 14.1 to 34.9 L/h (ciclosporin co-therapy) and from 11.9 to 25.4 L/h (tacrolimus co-therapy). Patient bodyweight, serum albumin concentration and immunosuppressant co-therapy have a significant influence on CL/F. The majority of pharmacodynamic data on MPA have been obtained in patients receiving mycophenolate mofetil therapy in the first year after kidney transplantation. Low MPA AUC is associated with increased incidence of biopsy-proven acute rejection. Gastrointestinal adverse events may be dose related. Leukopenia and anaemia have been associated with high MPA AUC, trough concentration and metabolite concentrations in some, but not all, studies. High free MPA exposure has been identified as a risk factor for leukopenia in some investigations. Targeting a total MPA AUC from 0 to 12 hours (AUC12) of 30-60 mg.hr/L is likely to minimise the risk of acute rejection and may reduce toxicity. IMPDH monitoring is in the early experimental stage. Individualisation of mycophenolate therapy should lead to improved patient outcomes. MPA AUC12 appears to be the most useful exposure measure for such individualisation. Limited sampling strategies and Bayesian forecasting are practical means of estimating MPA AUC12 without full concentration-time profiling. Target concentration intervention may be particularly useful in the first few months post-transplant and prior to major changes in anti-rejection therapy. In patients with impaired renal or hepatic function or hypoalbuminaemia, free drug measurement could be valuable in further interpretation of MPA exposure.

References

  1. Nephrol Dial Transplant. 2004 Oct;19(10 ):2630-3 - PubMed
  2. Ther Drug Monit. 2005 Jun;27(3):354-61 - PubMed
  3. Pediatr Nephrol. 2000 Feb;14 (2):95-9 - PubMed
  4. Transplantation. 1998 Jan 27;65(2):242-8 - PubMed
  5. Br J Clin Pharmacol. 2005 Sep;60(3):249-56 - PubMed
  6. Transplant Proc. 2005 Mar;37(2):856-8 - PubMed
  7. Ther Drug Monit. 2005 Jun;27(3):315-21 - PubMed
  8. Transplant Proc. 2004 Nov;36(9):2787-90 - PubMed
  9. Drug Saf. 2001;24(9):645-63 - PubMed
  10. Transplant Proc. 1998 Aug;30(5):1773-4 - PubMed
  11. Am J Transplant. 2004 Dec;4(12 ):2045-51 - PubMed
  12. Clin Chem Lab Med. 2000 Nov;38(11):1213-6 - PubMed
  13. Clin Transplant. 2000 Jun;14 (3):179-88 - PubMed
  14. Transpl Int. 1998;11 Suppl 1:S82-5 - PubMed
  15. Transplant Proc. 2003 Sep;35(6):2369-71 - PubMed
  16. Clin Pharmacokinet. 1998 Jun;34(6):429-55 - PubMed
  17. Ther Drug Monit. 2000 Feb;22(1):20-6 - PubMed
  18. Clin Pharmacol Ther. 2005 Jul;78(1):81-8 - PubMed
  19. Eur J Clin Pharmacol. 2005 Aug;61(7):507-16 - PubMed
  20. Ther Drug Monit. 2004 Jun;26(3):284-6 - PubMed
  21. Clin Sci (Lond). 2004 Jul;107(1):63-8 - PubMed
  22. Ann Pharmacother. 2003 Nov;37(11):1685-93 - PubMed
  23. Br J Clin Pharmacol. 2005 Mar;59(3):271-80 - PubMed
  24. Ther Drug Monit. 2001 Apr;23(2):119-28 - PubMed
  25. Clin Pharmacokinet. 2004;43(4):253-66 - PubMed
  26. Br J Clin Pharmacol. 2006 Oct;62(4):477-84 - PubMed
  27. Transpl Int. 2000;13 Suppl 1:S333-5 - PubMed
  28. Ther Drug Monit. 1999 Oct;21(5):498-506 - PubMed
  29. Nephrol Dial Transplant. 1999;14 Suppl 4:34-5 - PubMed
  30. Ther Drug Monit. 2001 Oct;23(5):514-9 - PubMed
  31. Liver Transpl. 2001 Aug;7(8):739-42 - PubMed
  32. Br J Clin Pharmacol. 1996 Jun;41(6):513-6 - PubMed
  33. Clin Chem. 1995 Jul;41(7):1011-7 - PubMed
  34. Clin Pharmacol Ther. 1999 Jun;65(6):640-8 - PubMed
  35. Ther Drug Monit. 2001 Dec;23 (6):717-21 - PubMed
  36. Am J Transplant. 2004 Mar;4(3):299-310 - PubMed
  37. J Clin Pharmacol. 2001 Mar;41(3):268-76 - PubMed
  38. J Clin Pharmacol. 2004 Jul;44(7):743-50 - PubMed
  39. Am J Transplant. 2004;4 Suppl 9:38-53 - PubMed
  40. Transplant Proc. 2004 Sep;36(7):2079-81 - PubMed
  41. Pediatr Nephrol. 2000 Feb;14 (2):100-4 - PubMed
  42. J Heart Lung Transplant. 1999 Feb;18(2):143-9 - PubMed
  43. Ther Drug Monit. 2005 Jun;27(3):378-88 - PubMed
  44. Transplantation. 2004 Jan 27;77(2):206-9 - PubMed
  45. Br J Pharmacol. 2001 Mar;132(5):1027-34 - PubMed
  46. Clin Pharmacol Ther. 2005 Jul;78(1):34-42 - PubMed
  47. Lancet. 1995 May 27;345(8961):1321-5 - PubMed
  48. Ther Drug Monit. 2000 Feb;22(1):14-9 - PubMed
  49. Liver Transpl. 2004 Apr;10 (4):492-502 - PubMed
  50. Clin Chem. 2001 Jan;47(1):88-94 - PubMed
  51. Lupus. 2005;14 Suppl 1:s2-8 - PubMed
  52. Transplant Proc. 2004 Apr;36(3):687-9 - PubMed
  53. J Clin Pharmacol. 2003 Aug;43(8):866-80 - PubMed
  54. Transplant Proc. 2000 Nov;32(7):1753-4 - PubMed
  55. Ther Drug Monit. 1994 Dec;16(6):602-7 - PubMed
  56. Clin Biochem. 2001 Feb;34(1):17-22 - PubMed
  57. Transplant Proc. 1998 Dec;30(8):4090-1 - PubMed
  58. Transplant Proc. 1998 Jun;30(4):1192-3 - PubMed
  59. Nephrol Dial Transplant. 2003 Apr;18(4):819-22 - PubMed
  60. Transplant Proc. 1995 Feb;27(1):1421-4 - PubMed
  61. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Jan 5;799(1):157-63 - PubMed
  62. Transplant Proc. 2005 Mar;37(2):864-6 - PubMed
  63. Clin Pharmacol Ther. 2000 Dec;68(6):613-6 - PubMed
  64. Transplant Proc. 2000 Mar;32(2):388-90 - PubMed
  65. Pediatr Transplant. 2005 Dec;9(6):780-7 - PubMed
  66. Transplant Proc. 1996 Apr;28(2):925-9 - PubMed
  67. Transplant Proc. 2001 Feb-Mar;33(1-2):1052-3 - PubMed
  68. Clin Pharmacokinet. 2005;44(8):837-47 - PubMed
  69. Transplantation. 1996 Apr 15;61(7):1029-37 - PubMed
  70. J Zhejiang Univ Sci B. 2005 Sep;6(9):885-91 - PubMed
  71. J Heart Lung Transplant. 2002 Oct;21(10 ):1074-9 - PubMed
  72. J Clin Pharm Ther. 2003 Feb;28(1):17-22 - PubMed
  73. Clin Chem. 2002 Sep;48(9):1497-504 - PubMed
  74. Pediatr Nephrol. 2001 Dec;16(12 ):978-84 - PubMed
  75. Transpl Immunol. 1997 Sep;5(3):225-32 - PubMed
  76. Transplant Proc. 2004 Sep;36(7):2076-8 - PubMed
  77. Drug Metab Dispos. 2005 Jan;33(1):139-46 - PubMed
  78. Br J Clin Pharmacol. 2001 Nov;52(5):605-9 - PubMed
  79. Transplant Proc. 2002 Aug;34(5):1745-7 - PubMed
  80. Am J Kidney Dis. 2004 Jun;43(6):1098-103 - PubMed
  81. Ther Drug Monit. 2001 Oct;23 (5):520-5 - PubMed
  82. Clin Sci (Lond). 2004 Jul;107(1):69-74 - PubMed
  83. Drug Metab Rev. 2001 Aug-Nov;33(3-4):273-97 - PubMed
  84. J Clin Pharmacol. 1996 Apr;36(4):315-24 - PubMed
  85. Ther Drug Monit. 2002 Apr;24(2):310-4 - PubMed
  86. Ther Drug Monit. 2004 Dec;26(6):600-8 - PubMed
  87. J Am Soc Nephrol. 1998 Aug;9(8):1511-20 - PubMed
  88. Br J Clin Pharmacol. 2003 Aug;56(2):188-97 - PubMed
  89. Clin Pharmacol Ther. 2004 May;75(5):434-47 - PubMed
  90. J Am Soc Nephrol. 2002 Mar;13(3):759-68 - PubMed
  91. Clin Biochem. 2001 Feb;34(1):77-81 - PubMed
  92. Ther Drug Monit. 2003 Oct;25(5):609-22 - PubMed
  93. Ther Drug Monit. 1999 Oct;21(5):536-9 - PubMed
  94. Pharmacotherapy. 1997 May-Jun;17 (3):591-8 - PubMed
  95. J Clin Pharmacol. 2002 Nov;42(11):1275-80 - PubMed
  96. Ther Drug Monit. 1999 Feb;21(1):35-43 - PubMed
  97. Clin Pharmacol Ther. 1998 Dec;64(6):672-83 - PubMed
  98. Kidney Int. 2002 Sep;62(3):1060-7 - PubMed
  99. Am J Transplant. 2003 Dec;3(12 ):1581-6 - PubMed
  100. Transplant Proc. 2002 Nov;34(7):2983-4 - PubMed
  101. Ther Drug Monit. 2003 Apr;25(2):137-57 - PubMed
  102. Clin Pharmacol Ther. 2005 Oct;78(4):351-61 - PubMed
  103. Transplantation. 1997 Jan 15;63(1):39-47 - PubMed
  104. Am J Transplant. 2004 Sep;4(9):1495-500 - PubMed
  105. Pharmacol Toxicol. 2000 Oct;87(4):182-4 - PubMed
  106. Transplant Proc. 1998 Aug;30(5):2237-9 - PubMed
  107. Ther Drug Monit. 2004 Aug;26(4):453-5 - PubMed
  108. Transplant Proc. 2005 May;37(4):1751-3 - PubMed
  109. Clin Chem. 2004 Jan;50(1):152-9 - PubMed
  110. Am J Transplant. 2005 Feb;5(2):199-200 - PubMed
  111. J Clin Pharmacol. 1996 Apr;36(4):332-44 - PubMed
  112. Am J Transplant. 2003 May;3(5):534-42 - PubMed
  113. Ann Clin Biochem. 2002 May;39(Pt 3):173-83 - PubMed
  114. Transpl Int. 2000;13 Suppl 1:S301-5 - PubMed
  115. Clin Transplant. 2005 Apr;19(2):199-206 - PubMed
  116. Transplant Proc. 1998 Jun;30(4):1185-7 - PubMed
  117. Liver Transpl Surg. 1999 Mar;5(2):101-6 - PubMed
  118. Clin Chem. 2001;47(7):1241-8 - PubMed
  119. Clin Biochem. 1998 Jul;31(5):323-8 - PubMed
  120. Drugs. 2005;65(8):1037-50 - PubMed
  121. Clin Pharmacol Ther. 2005 Oct;78(4):317-21 - PubMed
  122. Ann Pharmacother. 2003 Dec;37(12):1761-7 - PubMed
  123. Clin Chem. 2000 Mar;46(3):365-72 - PubMed
  124. J Clin Pharmacol. 2000 Jun;40(6):624-33 - PubMed
  125. Transplantation. 1995 Aug 15;60(3):225-32 - PubMed
  126. Am J Transplant. 2005 May;5(5):987-94 - PubMed
  127. Transplant Proc. 2004 Sep;36(7):2065-7 - PubMed
  128. Transplantation. 1999 Jul 27;68(2):261-6 - PubMed
  129. J Pharmacol Exp Ther. 2003 Aug;306(2):688-93 - PubMed
  130. J Chromatogr B Biomed Sci Appl. 1998 Apr 24;708(1-2):229-34 - PubMed
  131. Ther Drug Monit. 2002 Jun;24(3):390-9 - PubMed
  132. Transpl Int. 2005 Feb;18(2):140-50 - PubMed
  133. Clin Biochem. 1998 Jul;31(5):329-33 - PubMed
  134. Nephrol Dial Transplant. 1999;14 Suppl 4:33-4 - PubMed
  135. Clin Pharmacokinet. 2004;43(10 ):685-92 - PubMed
  136. Ther Drug Monit. 1998 Dec;20(6):685-90 - PubMed
  137. Ther Drug Monit. 1997 Jun;19(3):358-60 - PubMed
  138. J Chromatogr B Biomed Sci Appl. 2000 Oct 1;748(1):151-6 - PubMed
  139. Clin Pharmacol Ther. 1999 Nov;66(5):492-500 - PubMed
  140. Ther Drug Monit. 2001 Feb;23(1):35-8 - PubMed
  141. Transplantation. 1999 Nov 27;68(10):1603-6 - PubMed
  142. Transplant Proc. 2001 Feb-Mar;33(1-2):1040-3 - PubMed
  143. J Clin Pharmacol. 1999 Jul;39(7):715-20 - PubMed
  144. Transplantation. 1992 Feb;53(2):428-32 - PubMed
  145. Ther Drug Monit. 2004 Dec;26(6):620-5 - PubMed
  146. Transplant Proc. 1998 Jun;30(4):1299-302 - PubMed
  147. Transplant Proc. 2005 May;37(4):1748-50 - PubMed
  148. Clin Transplant. 2001 Dec;15(6):402-9 - PubMed
  149. Clin Biochem. 1998 Jul;31(5):317-22 - PubMed
  150. Transplantation. 2003 Mar 15;75(5):665-72 - PubMed
  151. Clin Transplant. 2003 Dec;17 (6):511-7 - PubMed
  152. Transplantation. 1997 Nov 15;64(9):1277-82 - PubMed
  153. Ther Drug Monit. 2004 Dec;26(6):609-19 - PubMed
  154. Transpl Int. 1998;11(1):53-7 - PubMed
  155. Am J Transplant. 2004 Feb;4(2):231-6 - PubMed
  156. J Clin Pharmacol. 2005 Jan;45(1):34-41 - PubMed
  157. J Am Soc Nephrol. 2003 Mar;14 (3):721-7 - PubMed
  158. Clin Biochem. 2001 Oct;34(7):543-9 - PubMed
  159. Ther Drug Monit. 2000 Oct;22(5):549-54 - PubMed
  160. Drug Metab Dispos. 2004 Jul;32(7):768-73 - PubMed
  161. Ther Drug Monit. 2005 Apr;27(2):132-8 - PubMed
  162. Ther Drug Monit. 2004 Aug;26(4):347-51 - PubMed
  163. Ther Drug Monit. 2002 Oct;24(5):598-606 - PubMed
  164. J Heart Lung Transplant. 2000 Nov;19(11):1071-6 - PubMed
  165. Transplant Proc. 2005 Jun;37(5):2320-3 - PubMed
  166. J Clin Pharmacol. 2005 Feb;45(2):219-26 - PubMed
  167. Clin Pharmacokinet. 2005;44(10 ):1083-96 - PubMed
  168. Transplant Proc. 1999 Feb-Mar;31(1-2):1135-7 - PubMed
  169. Transplant Proc. 2005 Mar;37(2):852-5 - PubMed
  170. J Pharmacol Exp Ther. 2003 Oct;307(1):117-28 - PubMed
  171. Clin Transplant. 2005 Aug;19(4):551-8 - PubMed
  172. Transplantation. 1998 Apr 27;65(8):1127-9 - PubMed
  173. J Clin Pharmacol. 1998 Mar;38(3):268-75 - PubMed
  174. J Heart Lung Transplant. 2003 May;22(5):587-90 - PubMed
  175. Ther Drug Monit. 2000 Feb;22(1):27-30 - PubMed
  176. Clin Biochem. 2000 Mar;33(2):107-13 - PubMed
  177. Ther Drug Monit. 2003 Feb;25(1):1-16 - PubMed
  178. Ther Drug Monit. 1995 Dec;17 (6):690-9 - PubMed
  179. Transplant Proc. 1998 Jun;30(4):1182-4 - PubMed
  180. Transplantation. 2000 Jun 15;69(11):2326-30 - PubMed
  181. Int J Clin Pharmacol Ther. 2003 Oct;41(10 ):470-6 - PubMed
  182. Transplant Proc. 2005 Mar;37(2):861-3 - PubMed
  183. Transplant Proc. 2001 Nov-Dec;33(7-8):3241-4 - PubMed
  184. Arzneimittelforschung. 2000 Oct;50(10):936-40 - PubMed
  185. Pharmacogenetics. 2004 Aug;14(8):501-15 - PubMed
  186. Ther Drug Monit. 2001 Aug;23 (4):305-15 - PubMed
  187. Br J Pharmacol. 1999 Mar;126(5):1075-82 - PubMed
  188. J Pharmacol Exp Ther. 2004 Jun;309(3):1029-35 - PubMed
  189. Transplant Proc. 2002 Nov;34(7):2985-7 - PubMed
  190. Transplantation. 2004 Aug 27;78(4):591-8 - PubMed
  191. Nephrol Dial Transplant. 1999 Mar;14 (3):706-8 - PubMed
  192. Ther Drug Monit. 2000 Apr;22(2):169-73 - PubMed
  193. Pharm Res. 1990 Feb;7(2):161-6 - PubMed
  194. Clin Pharmacol Ther. 1998 May;63(5):512-8 - PubMed
  195. Transplant Proc. 2005 Mar;37(2):859-60 - PubMed
  196. Drug Metab Dispos. 2004 Aug;32(8):775-8 - PubMed
  197. Transplant Proc. 2001 May;33(3):2163-4 - PubMed
  198. Clin Chem. 1999 Mar;45(3):419-22 - PubMed

Substances

MeSH terms

Publication Types